Article

High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage.

Department of Dermatology, University of Goettingen, Goettingen, Germany.
Annals of Hematology (impact factor: 2.62). 08/2007; 86(7):509-15. DOI:10.1007/s00277-007-0276-8
Source: PubMed

ABSTRACT In patients suffering from primary cutaneous lymphomas, secondary malignancies of various origin may develop. However, the frequency of a second neoplasm deriving from another lymphoid lineage is still unclear and may be underestimated. We screened all our patients with primary cutaneous lymphomas from a 4-year recruitment period for a coexisting secondary lymphoproliferative disorder. The cohort comprised of a total of 82 patients with primary cutaneous lymphomas, 62 with primary cutaneous T-cell lymphoma (CTCL), 18 with primary cutaneous B-cell lymphomas, and two with CD4+/CD56+ hematodermic neoplasm/blastic lymphomas. Seven patients (8.5%) were identified with a coexisting lymphoma of a different lymphoid lineage. Four patients with Sézary syndrome (SS) suffered from systemic B-cell lymphoma. Two of these developed SS after chemotherapy of their B-cell lymphoma. The other three patients with various types of skin lymphomas (SS, Mycosis fungoides [MF], primary cutaneous marginal zone lymphoma) developed Hodgkin's disease (hairy cell leukemia). Our data indicate that patients with primary cutaneous lymphomas have an elevated risk for the development of a secondary lymphoproliferative disorder even without previous chemotherapy. Possible explanations for this association include a genetic predisposition, alterations in early progenitor cells, underlying viral infections, and/or stimulation of a B-cell clone by the malignant helper T cells of the primary CTCL and vice versa.

0 0
 · 
0 Bookmarks
 · 
37 Views
  • Article: High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides.
    [show abstract] [hide abstract]
    ABSTRACT: Histopathology alone cannot predict the outcome of patients with CD30+ primary cutaneous lymphoproliferative disorders (CD30CLPD) and early mycosis fungoides (MF). To test the hypothesis that serum cytokines/cytokine receptors provide prognostic information in these disorders, we measured soluble CD30 (sCD30), sCD25, and selected cytokines in cell cultures and sera of 116 patients with CD30CLPD and 96 patients with early MF followed up to 20 years. Significant positive correlation was found between sCD30 levels and sCD25, CD40L, IL-6, and IL-8, suggesting that CD30+ neoplastic cells secrete these cytokines, but not Th2 cytokines. In vitro studies confirmed that sCD30, sCD25, IL-6, and IL-8 are secreted by CD30CLPD-derived cell lines. CD30CLPD patients with above normal sCD30 and sCD25 levels had worse overall and disease-related survivals, but only sCD30 retained significance in Cox models that included advanced age. High sCD30 also identified patients with worse survival in early MF. Increased IL-6 and IL-8 levels correlated with poor disease-related survival in CD30CLPD patients. We conclude that (1) neoplastic cells of some CD30CLPD patients do not resemble Th2 cells, and that (2) high serum sCD30, sCD25, IL-6, and perhaps IL-8 levels may provide prognostic information useful for patient management.
    Journal of Investigative Dermatology 11/2011; 132(3 Pt 1):703-10. · 6.31 Impact Factor

Keywords

4-year recruitment period
 
82 patients
 
B-cell lymphoma
 
CD4+/CD56+ hematodermic neoplasm/blastic lymphomas
 
coexisting lymphoma
 
different lymphoid lineage
 
genetic predisposition
 
lymphoid lineage
 
malignant helper T cells
 
Mycosis fungoides [MF]
 
primary cutaneous B-cell lymphomas
 
primary cutaneous lymphomas
 
primary cutaneous marginal zone lymphoma
 
primary cutaneous T-cell lymphoma
 
progenitor cells
 
secondary lymphoproliferative disorder
 
skin lymphomas
 
systemic B-cell lymphoma
 
three patients
 
various origin